References
- BROGDEN, R. N. and TODD, P. A., 1987, Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs, 34, 151–187.
- COOK, C. S., KARIM, A. and SOLLMAN, P., 1982, Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog. Drug Metabolism and Disposition, 10, 116–121.
- CUSIC, J. W. and SAUSE, H. W., 1965, 4-Dipropylamino-2-aryl-2-pyridyl-alkanamides. United States Patent, 3, 225,054.
- ECHIZEN, H., MOCHIZUKI, K., TANI, M. and ISHIZAKI, T., 1994, Interspecies differences in enantio-selective mono -N-dealkylation of disopyramide by human and mouse liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 268, 1518–1525.
- GIACOMINI, K. M., NELSON, W. L., PERSHE, R. A., VALDIVIESO, L., TURNER-TAMIYASU, K. and BLASCHKE, T. F., 1986, In vivo interaction of the enantiomers of disopyramide in human subjects. Journal of Pharmacokinetics and Biopharmaceutics, 14, 335–356.
- HEEL, R. C., BROGDEN, R. N., SPEIGHT, T. M. and AVERY, G. S., 1978, Disopyramide: A review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs, 15, 331–368.
- KARIM, A., RANNEY, R. E. and KRAYCHY, S., 1972, Species differences in the biotransformation of a new antiarrhythmic agent. Journal of Pharmaceutical Sciences, 61, 888–893.
- LE CORRE, P., GIBASSIER, D., SADO, P. and LE VERGE, R., 1992, Human pharmacokinetics and metabolism of disopyramide enantiomers. Laboratoire de Pharmacia Galenique et Biopharmacie, Université de Rennes I, France, 4, 80–83.
- LE CORRE, P., MALLEDANT, Y., CHEVANNE, F., SADO, P. and LE VERGE, R., 1991, Stereoselective biliary elimination of disopyramide and mono-N-desisopropyldisopyramide in humans. Labor atoire de Pharmacia Galenique et Biopharmack, Universite de Rennes I, France, 3, 233–237.
- LIMA, J. J., BOUDOULAS, H. and SHIELDS, B. J., 1985, Stereoselective pharmacokinetics of disopyramide enantiomers in man. Drug Metabolism and Disposition, 13, 572–577.
- PAULSON, S. K., ENGEL, L. C., REITZ, B., BOLTEN, S., BURTON, E. G., MAZIASZ, T. J., YAN, B. and SCHOENHARD, G. L., 1999, Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metabolism and Disposition, 27, 1133–1142.
- SZKLARZ, G. D. and HALPERT, J. R., 1998, Molecular basis of P450 inhibition and activation, implications for drug development and drug therapy. Drug Metabolism and Disposition, 26, 1179–1184.